Breaking News

Fujifilm Invests $83M to Expand Microbial Capacity

The expansion will take place in its Fujifilm Diosynth Biotechnologies’ Billingham, UK site

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Corporation has unveiled plans to invest approximately $83 million to expand the microbial production capacity of Fujifilm Diosynth Biotechnologies (FDB), a cGMP contract development and manufacturing organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies. The expansion will be made in its UK site and is scheduled to be operational after 2022. It will triple FDB’s current cap...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters